Valuation: Bioventix PLC

Market Cap 79.68M 106M 93.37M 86.83M 150M 10.24B 152M 1.03B 403M 5.03B 399M 390M 17.4B P/E 2026 *
11.4x
P/E 2027 * -
Enterprise Value 74.79M 99.78M 87.63M 81.5M 141M 9.61B 143M 968M 378M 4.72B 375M 366M 16.33B EV / Sales 2026 *
5.98x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
9.84%
Yield 2027 * -
1 day+1.67%
1 week-1.61%
Current month-7.58%
1 month-8.96%
3 months-10.29%
6 months-12.86%
Current year-19.95%
1 week 1,470
Extreme 1470
1,600
1 month 1,470
Extreme 1470
1,750
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,750
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Buy

Chief Financial Officer

534 0.0102%
4/28/26 Buy

Chief Financial Officer

66 0.0013%
4/20/26 Free

Chief Executive Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%-1.61%-43.93%-60.39% 106M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average +0.37%+0.59%+43.62%+87.90% 24.54B
Weighted average by Cap. +0.48%+0.91%+74.36%+136.18%

Financials

2026 *2027 *
Net sales 12.5M 16.68M 14.65M 13.62M 23.49M 1.61B 23.85M 162M 63.2M 790M 62.61M 61.26M 2.73B -
Net income 7.11M 9.49M 8.33M 7.75M 13.36M 914M 13.57M 92.03M 35.96M 449M 35.62M 34.85M 1.55B -
Net Debt -4.89M -6.53M -5.73M -5.33M -9.2M -629M -9.34M -63.33M -24.74M -309M -24.51M -23.98M -1.07B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-07-24 GBX 1,525.00 +1.67% 5,190
26-07-23 GBX 1,500.00 -3.23% 7,787
26-07-22 GBX 1,550.00 0.00% 33,296
26-07-21 GBX 1,550.00 0.00% 13,064
26-07-20 GBX 1,550.00 0.00% 11,168
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock